HC Wainwright began coverage on shares of Surrozen (NASDAQ:SRZN – Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $32.00 price target on the ...

Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst R. Burns now ...

H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the ...

H.C. Wainwright adjusted its price target for McEwen Mining (NYSE:MUX) shares, reducing it to $18.00 from the previous $19.00 ...

H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has initiated coverage on the ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China ...